A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy

Trial Profile

A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms A-PREDICT
  • Most Recent Events

    • 16 May 2017 Final data on response and toxicity of axitinib will be available in second quoter of 2017 as per results presented at the 112th Annual Meeting of the American Urological Association
    • 16 May 2017 Results (n=65) presented at the 112th Annual Meeting of the American Urological Association
    • 15 Nov 2016 Last checked against European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top